{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:26:42Z","timestamp":1790879202646,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.bcmd.2011.11.001","type":"journal-article","created":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T09:03:09Z","timestamp":1323162189000},"page":"132-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib"],"prefix":"10.1016","volume":"48","author":[{"given":"Douglas","family":"Vivona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina T.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciene T.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario D.C.","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario H.","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 D.","family":"Luchessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Zanichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos S.","family":"Chiattone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira M.","family":"Guerra-Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2011.11.001_bb0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"Mechanisms of disease \u2014 the biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000046634","article-title":"An overview of translocation-related oncogenesis in the chronic myeloid leukaemias","volume":"107","author":"Bain","year":"2002","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0025","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.11.001_bb0030","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","article-title":"Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1","volume":"1587","author":"Hegedus","year":"2002","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0035","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of imatinib mesilate with human P-glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0040","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4161\/cc.3.12.1331","article-title":"Pharmacokinetic resistance to imatinib mesylate \u2014 role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib","volume":"3","author":"Burger","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcmd.2011.11.001_bb0045","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF00272381","article-title":"Localization of the human multiple-drug resistance gene, mdr1, to 7q21.1","volume":"77","author":"Callen","year":"1987","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0055","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gr.184901","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0060","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbapap.2009.02.014","article-title":"A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function","volume":"1794","author":"Fung","year":"2009","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"key":"10.1016\/j.bcmd.2011.11.001_bb0065","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0070","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bcmd.2011.11.001_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans","volume":"70","author":"Kim","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0080","first-page":"406","article-title":"Drug transporters and Imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.bcmd.2011.11.001_bb0090","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0095","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.bcmd.2011.11.001_bb0100","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1590\/S0100-879X2005000900014","article-title":"High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent","volume":"38","author":"Rodrigues","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"3","key":"10.1016\/j.bcmd.2011.11.001_bb0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","article-title":"Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects (vol 69, pg 169, 2001)","volume":"69","author":"Cascorbi","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.2004.00228.x","article-title":"Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia","volume":"72","author":"Jamroziak","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0150","article-title":"MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis","author":"Penna","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1026331326648","article-title":"Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T Polymorphisms","volume":"136","author":"Goreva","year":"2003","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.leukres.2008.06.008","article-title":"Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1\/ABCB1) and risk of multiple myeloma","volume":"33","author":"Jamroziak","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2011.11.001_bb0130","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2011.11.001_bb0135","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"318","key":"10.1016\/j.bcmd.2011.11.001_bb0140","first-page":"1382","article-title":"A \u201cSilent\u201d polymorphism in the MDR1 gene changes substrate specificity","volume":"30","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2011.11.001_bb0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2011","journal-title":"Med. Oncol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979611002002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979611002002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:27:55Z","timestamp":1761049675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979611002002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1079979611002002"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2011.11.001","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2011.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}